Engaging Stakeholders

Part I of this article covered Ron Yustein’s discussion of the CDRH Signal Management Program. Part II goes into detail on agency policies and actions regarding stakeholder engagement.

Medical device manufacturers, did you know there are times when the Center for Devices and Radiological Health (CDRH) will inform the public that FDA has concerns about a marketed device before contacting the company? Why is this? What does CDRH’s signal detection and evaluation process look like and how does the agency engage the various stakeholders?

[Related: Panelists Mark Agostino and Alison Sathe discussed postmarket surveillance requirements under the EU MDR during a recent virtual panel discussion. You can download the full recording here.]

Webinar ad - download

At the FDA/Xavier Health MedCon conference held virtually earlier this year, Associate Director for the Postmarket Program in the CDRH Office of Product Evaluation and Quality (OPEQ) Ron Yustein addressed these and other questions in a presentation titled, “Postmarket Surveillance and Signal Management at CDRH—Engaging Stakeholders.”

As background, Yustein referenced a public workshop CDRH hosted in November 2020. “The focus of that meeting was on medical device safety communications. But there really was quite a bit of discussion about postmarket signals. And really, those two processes, signal management, and communications, are really closely linked.”

Although there are multiple types of stakeholders, including patients, clinicians, hospitals, and the media, most of the participants were from industry. The most common theme from Yustein’s perspective was that CDRH should engage impacted manufacturers and clinicians earlier and more often during its evaluation of identified safety signals and in the preparation of safety communications.

CDRH Engages with Manufacturers

Yustein commented that sometimes the agency hears from a company that it was not fully aware FDA was evaluating a safety issue related to its product.

“Here are a few things that if I were working for a manufacturer might cause me to pause and think that FDA has some potential safety concerns, regardless of the time point or where it is coming from. I am not saying all these mean that FDA has started a formal cross-center evaluation, because they can occur at different stages, including the earliest detection phases. These are in no specific order.”

  • Safety-related deficiencies that appear in a premarket submission: Although it is uncommon to lead to a formal safety signal from a postmarket standpoint, if the product is already marketed and the submission is making device or labeling modifications, premarket reviewers’ interest in safety issues may arise and you may see some questions in deficiency letters regarding that.
  • For those situations where a sponsor is conducting a mandated postmarket study, such as a post-approval study, or a 522 study, deficiency questions that focus on some of the interim and final safety results may indicate that we have some potential concerns.
  • Manufacturers often get what are called “Additional Information,” or AI letters, from FDA staff who review medical device reports (MDRs) seeking additional information on the device such as, what happened to the device? What happened to the patient? What happened during the event? In one or more MDRs there may be a signal that an FDA reviewer is looking into what they consider to be a newer, significant safety concern.
  • Receipt of an “Information Request Letter” (IRL) from a CDRH safety signal coordinator, and
  • Two that are much later in the process—receipt of a compliance letter or directed inspection, or FDA issuing a safety communication or public message.

“I certainly recognize that the public message is not the preferred way to learn that FDA has concerns about a device, but it can happen sometimes for a variety of reasons as the first indicator.”

[Editor’s Note: In the video clip below, medical device experts Mark Agostino and Alison Sathe discuss why companies marketing medical device products to the EU marketplace should take a risk management approach to postmarket surveillance.]

The Information Request Letter

The IRL is one that comes from an Office of Health Technology (OHT) within OPEC when it is evaluating a safety issue that has been entered into the program tracking system and has been assigned to an issue lead and the team has met and started discussing the issue.

“As with most other things we call it a letter, but it will show up as an email,” the CDRH official explained. “We do our best to find the right person at the manufacturer to communicate with, but it is not always as easy as it sounds. Many times, our OHT premarket staff know the main regulatory contacts for the device based on recent submissions. But sometimes we must rely on information in the registration and listing system, and those are not always accurate. Whether either of those sources is the correct contact that the manufacturer would prefer for this kind of communication is not something that we are always sure of.”

An information request letter states that the agency is evaluating a safety issue and is seeking information or data from the manufacturer. It describes the issue and how CDRH became aware of it, what the source of the information was, and then it goes on with a series of one or more questions with a requested response date. Often that is 30 days, but sometimes if the issue is more pressing, the agency may request shorter turnaround times.

Yustein commented that sometimes the agency hears from a company that it was not fully aware FDA was evaluating a safety issue related to its product

The letter does have the name and contact information for the FDA issue lead or safety signal coordinator and “certainly the industry should feel free to contact that person by email or phone should they want some additional clarification or further discussion on the issue or with the questions that are in the letter,” Yustein pointed out. “Upon receipt of the responses and an evaluation by the FDA team, we may certainly have additional new questions, which would then come back to you by a similar process.”

“With any of our processes, there are limitations,” he commented. “I discussed one earlier—finding the right person at the company to correspond with.”

“Two others are related to class signals. One is identifying who the impacted manufacturers are with the limitations of the registration and listing system. Sometimes if a particular product type has numerous manufacturers and numerous models, it is difficult for us to always pin all those down. The other issue we run into is where there are numerous impacted firms as we have limits on what we can do based on what is called the paperwork reduction act.”

Sometimes CDRH may not actually need additional information from the manufacturers themselves as the data it does have could be sufficient to understand the issue and guide the next steps. So, the agency does not send IRLs for all signals.

Safety Communication Process

FDA issues safety communications on some of its signals. They usually take the form of a public safety communication, or “Dear Healthcare Professional” letters, sometimes called a “Dear Doctor” letter. But there are other vehicles, including consumer update Web pages and FDA Voices articles.

The Signal Management Program works closely with and uses CDRH communication experts and risk communication people and their processes. Any recommendation from a signal management team requires concurrence from senior leadership before proceeding with the communication. The final communications also go through leadership clearance before being issued.

We do our best to find the right person at the manufacturer to communicate with, but it is not always as easy as it sounds

Traditionally, the agency tries to call impacted manufacturers at least 24 to 48 hours ahead of posting the communication so that the manufacturers can be prepared.

“During those calls, we typically summarize what the communication will say, when it will be posted and where. This may or may not happen with every communication, especially if we are dealing with large class signals where we are not calling out a specific product by name and we are contacting dozens of manufacturers. In those cases, it is really not practical.”

Interacting with Other Stakeholders

Besides interactions with industry, the agency does have processes to interact with members of the clinical and end-user facility communities.

“During our signal evaluations we have a great breadth of clinical expertise from clinicians within the Center and the agency, but we do occasionally reach out on complicated issues,” Yustein explained.

“We have certainly received a few signals from these communities, but we probably more frequently use them during the refinement process. Often, they help us better understand and characterize the extent and impact of the issue, how it can be identified, prevented, or addressed in real-world settings.”

Some of the methods used include:

  • The “Network of Experts” program, which we have in affiliation with multiple professional societies
  • Tapping into experts who are Special Government Employees
  • Discussion with clinicians or risk managers at user facilities or other government facilities
  • The more public advisory committee meeting forum

“We also have newer processes to interact with patients or patient groups. We receive safety signals from individual patients or patient groups either through MDRs, emails, complaints, allegations, and sometimes phone calls. We are looking to improve how we interact more consistently with them during the signal evaluation process.”

The Center has recently set up different vehicles to promote these interactions, including the Patient Engagement Advisory Committee (PEAC), Patient Engagement Conversations, and Patient and Caregiver Connection, which is similar to the network of experts program it uses to interact with professional societies. CDRH also heard at the November meeting in 2020 that patients would like more engagement with FDA during the safety communication process and message testing of safety communications.

CDRH does occasionally interact with or coordinate evaluations and actions with a host of federal health agencies including the CDC, National Institutes of Health, the Consumer Product Safety Commission, and the military, as well as state health departments and regulatory bodies outside of the United States, many of whom it has confidentiality agreements with along with regular meetings.

Final Thoughts

“I think we all agree that more engagement is better. But at the same time, I think it is important to remember that increased engagement does come at an increased cost as it does require people and time,” Yustein commented.

“It is important to remember that from FDA’s perspective we have many individual companies and groups who are seeking increased engagement with us simultaneously. Throughout this, it is important for FDA to keep a level playing field. This includes the fact that FDA is bound by certain rules about confidentiality and disclosure of nonpublic information, and those sometimes can impede how much we can say to certain parties at certain times.”

[Related: Learn more about postmarket surveillance requirements under the EU MDR by downloading the recording of the recent virtual panel discussion, “Changing Medical Device Regulations.”]

Webinar ad - download

Download the Special Report

Quality Week report sidebar

What You Will Learn from This Report:

How a major pharmaceutical company designed a program to train future leaders in quality

An industry-led initiative to advance the state of quality in the pharma industry

A pharma GMP leader’s tips for supporting quality culture within an organization

An update on FDA’s Quality Maturity Model

Redica Systems Enforcement Analytics

Compare two companies of your choice.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Evaluate Your CDMOs

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Compare the inspection history of your CDMO sites.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Compare the enforcement history of your CDMOs.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Monitor compliance at your Clinical Investigator sites.

Enter your email address and someone will contact you shortly to get you started.

Redica Systems Enforcement Analytics

Prepare for inspections of Clinical Investigator sites.

Enter your email address and someone will contact you shortly to provide more Clinical Investigator data about your sites.

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore enforcement trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore observations and trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to run your custom report.

Redica Systems Enforcement Analytics

Get help choosing the right CRO.

Enter your email address and someone will contact you shortly to customize your insights.

Download the Special Report

Download your copy of THE FDA INSPECTION LANDSCAPE IN MID-2020 AND A LOOK AT VIRTUAL INSPECTION

In this summary we identify:

  • Trend analysis of FDA inspections through mid-2020
  • Strategies for preparing and hosting virtual inspections
  • New technologies to support remote inspections
Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need to prepare for your next inspection.

Download the Special Report

CDMO Comparison opt-in

In this summary we identify:

FY2018-FY2020 GMP data for Lonza & Catalent

Top GMP primary citations

Top FDA 483 observations

Panel Discussion – Remote Audits

Panel Discussion opt in image

Featuring Panelists:
—Barbara W. Unger, Unger Consulting, Inc.
—Jerry Chapman, Redica Systems
—Stephanie Gaulding, Pharmatech Associates

Who Will Benefit?
This session will be valuable to GMP quality, regulatory, compliance, and management personnel in FDA-regulated industries who want to have a conversation on remote audits and get to know what is going on in the industry.

Turning Failure into Success

Presented on Tuesday, April 27, 2021 by Steve Greer, Executive Coach, Genesis Assist, and former Quality Leader, Procter and Gamble

What you will learn:

  • How to use the Leadership SOS Model to transform quality culture
  • How to strengthen quality systems to eliminate human error
  • How to generate ideas on how to set your organization up for success for shareholders, FDA, and staff
Redica Systems Enforcement Analytics

Get Full Access to Redica Enforcement Analytics

Enter your email address and someone will contact you shortly to answer all of your questions and get you started.

Quality Management Systems for Small Pharma and Biotech Firms

Webinar: QMS for Small Pharma and Biotech Firms

Presented by Fenton Fong, Founder, Managing Director, & Principal at xCellarate

Get instant access to the webinar video and slides.

What you will learn:

  • Common challenges small pharma firms face when developing a QMS
    Recent enforcement trends involving the Quality Unit
    Impact of the COVID-19 pandemic

Download the Special Report

APAC ad

In this summary we identify:

GMP data from FY2017 to FY2020 for the Asia-Pacific region

Top 3 GMP primary and secondary citations

Top 3 483 observations

Download the Special Report

An Analysis Of MHRA’s Latest Annual GMP Inspection Deficiencies Report

In this summary we identify:

  • Data from 2019 UK MHRA Inspections
  • Trends from 2015, 2016, 2018, and 2019 inspections
  • Conclusions drawn from an analysis of drug inspection data

Experience the Power of Redica Systems

Redica_Vert_Periwinkle_RGB_Large

SEARCH Find the inspection records you want by inspector’s name, company name, site, city, country, etc.

WARNING LETTERS Easily search the largest database of FDA Warning Letters by date, company, FDA office, or subject

SITES Quickly assess inspection records including dates and inspectors across all of your sites

INSPECTIONS Complete list of FDA inspections by date, company, category, and country

Get Complete Access to the Redica Systems Platform

Please submit your email address and one of our team members will contact you shortly to answer all of your questions and get you started with the new Enforcement Analytics platform.

Experience the Power of Redica Systems

Complete the form and one of our experts will reach out to you to schedule a demo and answer questions about our subscription options.

INDEX INFORMATION  Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

STRENGTHEN DATASETS Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

ANALYZE & INTERPRET PATTERNS Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Impact of the Global Pandemic on Recent Data Integrity and Regulatory Non-compliance Trends

Webinar: Impact of the Global Pandemic on Recent Data Integrity and Regulatory Non-compliance Trends

Presented by Paul Smith, Agilent Technologies on Aug. 26, 2020

What you will learn:

  • Examples of essential laboratory actions to remain compliant during the pandemic
  • Recent data integrity non-compliance findings and trends
  • Essential strategies to find, understand, and leverage regulatory non-compliance data

Get the scoop on recent data integrity 483 observations!

  • FY 2020 Data Integrity 483 Observations
  • Data Integrity Observations for Human Drugs
  • Observations Falling Under GMP
  •  

Past, Present, and Future of Quality Culture

Presented by Regulatory Compliance Associates Distinguished Fellow Susan Schniepp

What you will learn:

  • How the 2014 FDA quality metrics initiative led to greater focus on quality culture
  • New quality culture tools and standards under development by PDA and other organizations
  • Best practices for quality culture, including case studies with lessons learned

Changing Medical Device Regulations

Presented by Redica Systems 

What you will learn:

  • The latest developments regarding the EU MDR
  • Quality Systems requirements for medical devices
  • Regulatory updates affecting medical devices

Download the Special Report

Combination Product Report

What You Will Learn from This Report:

The latest U.S. and European regulatory developments

The impact of smart combination products

How the EU MDR impacts drug-device combination products

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

In-depth analysis of the findings

Lessons learned

How companies can avoid similar shortcomings.

Experience the Power of Redica Systems

Redica Systems Expert Jerry Chapman to Present at SQA Annual Meeting

Index Information Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

Strengthen Datasets Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

Analyze & Interpret Patterns Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Download the 510(k) Sample

What You Will Learn from This Sample:

See how a 510(k) submission is structured

Find out what information to include

Review correspondence between sponsor and FDA

Redica Systems Enforcement Analytics

Unlimited Access to Reports and Data

Enter your email address and someone will contact you shortly.

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

The first countrywide import alert issued by FDA

An inadequate deviation investigation

An inadequate product specifications and a product recall

Process validation issues at a CMO

A different perspective on process validation and the culpability of the quality unit

 

A.I. for Quality and Compliance Teams

August 3 webinar

Presented by Redica Systems Senior GMP Quality Expert Jerry Chapman

What you will learn:

  • A basic understanding of data sources, machine learning, NLP, and A.I. tools
  • Building and applying Expert Models
  • Two case studies, one on sterile manufacturing/503B and one on data integrity

Human Factors – Compliance and Applications

June webinar

Presented by Alison Sathe, Founder, Regulatory Mark & Valerie Fenster, Director of Insights and  Human Factors, Kaleidoscope Innovation 

What you will learn:

  • Human factors strategies from simple drug products to complex surgical devices
  • Primary and secondary labeling development and evaluation for usability
  • Human factors activities from product development to post-market
  • International strategies: expectations for human factors in regulatory submissions in international markets

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Sign up for your FREE account today and get instant access to Enforcement Analytics.

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Let us know who you are and we’ll be in touch to answer all of your questions and get you started.

Redica Systems Enforcement Analytics

Keep up with the latest Regulatory Developments on Clinical Trials

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save your team valuable time when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save time and Resources when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Get immediate access to the news that matters to your sites.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

See how we can help you eliminate yet another spreadsheet.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Stay ahead of changing regulations.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your CDMO monitoring strategy.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your CDMO management strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Discover the power of the most comprehensive database of 483s in existence.

Our database of over 20,000 483s is retyped and tagged, making it easy to create an Observation Report in seconds.

Eliminate days of work and get your FREE personalized 483 Observation Report.